Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry as of March 1, 2026 [1] Core Insights - The supply-side variables in the pharmaceutical industry are increasing, leading to an expansion in price adjustments. The raw material drug industry is particularly sensitive to these changes, with the penicillin supply chain already experiencing price rebounds. For instance, the import price limit for 6-APA has been set at approximately 260 RMB/kg, prompting domestic companies to raise their prices [2] - The GLP-1 oral medication era is actively beginning, with Chinese companies continuing to explore international markets. Notably, Eli Lilly's sales of its GLP-1 drug reached 36.5 billion USD in 2025, and the oral version of semaglutide has been launched in the U.S. market, showing strong initial prescription numbers [3] - The small nucleic acid field is witnessing ongoing collaborations and authorizations, with significant mergers and acquisitions occurring in 2026. For example, China National Pharmaceutical Group is acquiring a domestic siRNA innovator for 1.2 billion RMB [4] - The retail pharmaceutical market showed positive trends in Q4 2025, with a retail scale of 58.8 billion RMB, although the annual growth rate remained slightly negative at -0.57% [5] - The report emphasizes the market value of oral autoimmune drugs, highlighting Takeda's new oral TYK2 inhibitor showing promising results in clinical trials for psoriasis [6] Summary by Sections 1. Pharmaceutical Market Tracking - The pharmaceutical industry index underperformed the CSI 300 index by 0.58 percentage points in the last week, ranking 25th among 31 sectors [19] - Over the past month, the pharmaceutical industry index fell by 2.67%, also underperforming the CSI 300 index by 2.77 percentage points, ranking 28th [22] 2. Pharmaceutical Sector Trends and Valuation - The current PE (TTM) for the pharmaceutical industry index is 37.20, which is below the five-year historical average of 30.78 [40] 3. Recent Research Achievements - The report includes various deep-dive studies on topics such as the growth of biological agents and oral medications, indicating a positive outlook for psoriasis treatment [42] 4. Important Industry Policies and News - Recent policies include the approval of 292 medical device products by the National Medical Products Administration, indicating regulatory support for the industry [44] - Significant news includes Eli Lilly's positive clinical trial results for its drug, which may enhance its market position [46]

Core Viewpoint - Novo Nordisk (NVO.US) announced the launch of two oral weight loss medications, Wegovy, for self-paying patients in the U.S. starting January 5, with monthly prices set at $149 for the 1.5 mg and 4 mg doses, and $299 for the higher doses of 9 mg and 25 mg [1] Pricing Strategy - The 4 mg dose price will increase to $199 per month starting April 15 [1] - The pricing strategy aims to enhance Novo Nordisk's competitive position against Eli Lilly (LLY.US) in the market [1] Regulatory Approval - The U.S. Food and Drug Administration (FDA) approved the oral medication on December 22 of the previous year, marking a significant milestone for the company [1] Product Information - The newly approved oral semaglutide tablets contain the same active ingredients as the injectable Wegovy and Ozempic, and will be marketed under the Wegovy brand [1] - Novo Nordisk has previously launched an oral semaglutide medication, Rybelsus, aimed at treating type 2 diabetes [1]